400-0512-686

News

News
Location:Home >News >News

光景生物体外诊断产品入选国家科技部创新医疗器械产品目录

Poptime:2018-12-10 Page View:778

科技部印发了《“十三五”医疗器械科技创新专项规划》,在该规划中提出了要促进医疗器械创新产品推广。其中,就要提到要出台“创新医疗器械产品目录,打造一批国产创新品牌”。同时,积极探索财政引导支持方式,加强招标采购激励机制设计,合理运用服务收费、医保政策,引导国产设备使用;加大对国产创新产品的宣传力度,提高国产创新医疗器械产品的社会认同度;支持符合条件的高端医疗器械装备市场应用推广,在部分省(市)开展大型医疗设备配置试点;结合“一带一路”战略,促进国产医疗器械支撑的新型卫生与健康服务在沿线国家的推广应用,助力国产医疗器械进入国际市场。
    光景生物科技(苏州)有限公司研发生产国内首创的时间分辨荧光免疫分析仪通过科技部《创新医疗器械产品目录》遴选并公示,这既是对我公司的鼓励,也是对产品质量的肯定。在今后的工作中,光景同仁必将继续拼搏努力,力争以优质的产品和服务,成为国内一流、国际领先的体外诊断产品研发、生产及销售的领军企业之一。

Earlier
April 2014

Lumigenex receives CFDA approval for four POCT immunoassay kits to help physicians quickly and accurately diagnose heart diseases.

March 2014

Lumigenex receives CFDA approval for five immunoassay reagents adaptable to most chemical analyzers.

February 2014

Lumigenex received CFDA approval for time-resolved fluorescence immunochromatographic analyzer.

January 2014

Dr. He Aimin was named "National Thousand Talents Program"

December 2013

Lumigenex access to "high-tech enterprises in Jiangsu Province" title.

September 2013

Lumigenex passed The first Food and Drug Administration by the Suzhou Municipal Quality Management System Assessment.